Skip to main contentSkip to navigationSkip to search
Curasight

Curasight A/S presents at Nordnet Live - Spotlight Small Cap investor conference 15 April 2021

April 9, 2021

Regulatory

Curasight A/S CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company and its future plans, at the Nordnet Live platform 15 April 2021, 16:20 (CET). The presentation will be webcasted live.

For more information and registration – please click here

The event will be moderated by Brian Buus (Head of Business Management, Nordnet)

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: [email protected]

www.curasight.com

Downloads

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.